Enliven Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income $23.6 million.
“Enliven reported a net loss of $23.6 million for the first quarter of 2026”
Enliven Therapeutics, Inc. — fact timeline
Source-grounded facts extracted from Enliven Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Enliven Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income $22.7 million.
“Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update”
Lori Kunkel was appointed as Class III Director at Enliven Therapeutics, Inc..
“On April 8, 2024, the Board of Directors (the “Board”) of Enliven Therapeutics, Inc. (the “Company”) appointed Lori Kunkel, MD to serve as a Class III director, with a term expiring at the Company’s 2026 annual meeting of stockholders.”
Enliven Therapeutics, Inc. entered into Purchase Agreement with the purchasers named therein valued at approximately $90 million (effective 2024-03-19).
“On March 19, 2024, Enliven Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), for the private placement (the “Private Placement”) of (i) 5,357,144 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at $14.00 per Share, and (ii) pre-funded warrants (the “Pre-Funded Warrants") to purchase 1,071,505 shares of Common Stock”
Enliven Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income net loss of $19.4 million for the fourth quarter of 2023.
“Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today reported financial results for the fourth quarter and full year ended December 31, 2023”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.